ERBB2 and breast carcinoma: Furthermore, as we know, the preferred NAC regimens and efficacy are different for different breast cancer subtypes (according to ER, PR, and HER2 status), and there is a lack of sufficient patients to support a more detailed study of the same subtype and the same treatment regimen, which will be further refined in the future when more patients are available or data from more centers are included.